Anya John

Anya John, on behalf of Akash Tewari, asked for more details on Alkermes' ADHD study for ALKS 7290, specifically if they are considering enriching the population for any specific ADHD phenotypes.

Answer

Richard Pops, CEO of Alkermes, stated they are not enriching for any particular phenotype or chronotype. He expects to discern dose response and efficacy signals quickly in a small patient cohort, similar to their narcolepsy approach.

Anya John asked for more details about Alkermes' ALKS 7290 ADHD study, specifically whether they are considering enriching the patient population for any specific ADHD phenotypes.

Answer

Richard Pops, CEO, stated that Alkermes is not planning to enrich for any particular phenotype or chronotype in the ADHD study. He expressed confidence in discerning dose response and efficacy signals in a relatively small cohort of patients within a short timeframe, similar to their approach in narcolepsy.